Advocating for Health Equity

Shaping a new era of global health investment, policy, planning and prevention

AVAC Meeting in NYC

Advocacy and activism have been a linchpin in the history of HIV treatment and prevention. The visionary work of passionate advocates has resulted in hard-fought global gains against HIV.

AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.

Our advocacy takes place:

  • Where funders, policies and programs come together.
  • At the point of service delivery, where options from the pipeline must become choices in people’s lives. 
  • At Parliaments, State Houses, Ministries of Health, National legislatures, and international bodies,to press for global and country accountability.
  • In the hands of robust and sophisticated coalitions of African-led civil society organizations.

The Latest on Advocating for Health Equity

Press Release

AVAC Condemns Administration’s Further Actions to Dismantle and Deconstruct U.S. Government Vaccine Research and Delivery Infrastructure

AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines.

Event

Fight for Firewalls: HIV and Health Data Privacy in the Snowballing Surveillance State

With the increased abuse of technology in surveilling and criminalizing healthcare, especially abortion and gender affirming care, more and more people are asking: is my personal health data safe? Kendra Albert, a public interest technology lawyer, discussed the current state of health data privacy, especially as it relates to people living with HIV. Participants learned basic concepts in health data privacy and what actions they can take to improve health data privacy on the state level.

Infographic

LEN Generics — Can we go faster?

The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.